课题基金 / 基金详情

项目摘要

项目成果

Bruce E. Landon的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Project Summary: Ruptured abdominal aortic aneurysm (AAA) is the 10th leading cause of death in men over age 55 in the US with mortality of ruptured AAA exceeding 80%. Up until recently, to prevent ruptures, elective Open AAA repair was typically performed with mortality of d5%. Within the last decade, endovascular AAA repair was introduced as a less invasive alternative to open repair. FDA approval for stentgraft repair of AAA in the United States was granted in 1999 and the use of endovascular repair has steadily grown since that time, replacing open surgery for many patients. Over 40,000 AAA repairs are performed annually in the United States and by 2005, 56% of all elective AAA repairs performed in the Medicare population were endovascular. Endovascular AAA repair has been shown to have a lower operative mortality and morbidity than open repair in short-term head to head comparisons. However, recent randomized trials have not demonstrated a sustained mortality benefit with endovascular repair. Endovascular repair also requires costly follow-up surveillance and there is a greater need for re-interventions, although endovascular technologies continue to evolve. In order to understand the comparative effectiveness of various interventions, it is important to extend inquiry beyond small randomized controlled trials of ideal populations to study interventions in real world settings using observational data. In the case of AAA repair, access to comprehensive data from the Medicare program represents an ideal setting in which to perform comparative effectiveness studies as the vast majority of AAA repairs (70%) are performed in this elderly population. Medicare data are also ideally suited to studies that include longer term follow-up and the occurrence of uncommon complications. The specific aims of this proposal are: 1) To study the long term outcomes of endovascular versus open AAA repair in a comprehensive sample of Medicare patients undergoing elective repair; 2) To determine whether changes in technology, as measured by the introduction of new endovascular products over time, has impacted both perioperative and long term survival of those undergoing endovascular repair; and 3) To rigorously define, quantify, and measure the impact of laparotomy related complications in the case of open AAA repair and graft-related complications in the case of endovascular repair.
期刊论文(3)
专著(0)
科研奖励(0)
会议论文
Improving observational study estimates of treatment effects using joint modeling of selection effects and outcomes: the case of AAA repair.
使用选择效应和结果的联合建模改进治疗效果的观察性研究估计:AAA 修复案例。
DOI: 10.1097/mlr.0b013e3182363d64
发表时间: 2011
期刊: Medical care
影响因子: 3
作者: [O'Malley,AJames, Cotterill,Philip, Schermerhorn,MarcL, Landon,BruceE]
通讯作者: Landon,BruceE
Risk Aversion, Fear of Malpractice, and Medical Decision Making in the Emergency Department
  • 批准号:
    10474364
  • 项目类别:
  • 资助金额:
    $38.36万
  • 财政年份:
    2019
  • 负责人:
    Bruce E. Landon
  • 依托单位:
Comparing Targeted and Non-Targeted Approaches to Improving the Value of Cancer Care Services
  • 批准号:
    9895590
  • 项目类别:
  • 资助金额:
    $37.18万
  • 财政年份:
    2019
  • 负责人:
    Bruce E. Landon
  • 依托单位:
Risk Aversion, Fear of Malpractice, and Medical Decision Making in the Emergency Department
  • 批准号:
    10242666
  • 项目类别:
  • 资助金额:
    $39.03万
  • 财政年份:
    2019
  • 负责人:
    Bruce E. Landon
  • 依托单位:
Comparing Targeted and Non-Targeted Approaches to Improving the Value of Cancer Care Services
  • 批准号:
    10374837
  • 项目类别:
  • 资助金额:
    $40.0万
  • 财政年份:
    2019
  • 负责人:
    Bruce E. Landon
  • 依托单位:
国内基金
海外基金
补阳还五汤通过AGE-RAGE通路调控脓毒症免疫失衡的机制与转化研究
靶向递送一氧化碳调控AGE-RAGE级联反应促进糖尿病创面愈合研究
  • 批准号:
    JCZRQN202500010
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2025
  • 负责人:
  • 依托单位:
对香豆酸抑制AGE-RAGE-Ang-1通路改善海马血管生成障碍发挥抗阿尔兹海默病作用
  • 批准号:
    2025JJ70209
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2025
  • 负责人:
    雷芬芳
  • 依托单位:
AGE-RAGE通路调控慢性胰腺炎纤维化进程的作用及分子机制
  • 批准号:
    --
  • 项目类别:
    面上项目
  • 资助金额:
    --
  • 批准年份:
    2024
  • 负责人:
    万荣
  • 依托单位: